Ongoing Phase I clinical trial (JPH034) being conducted in the United States
In order to lay the foundation for future global development, we will evaluate safety, tolerability, pharmacokinetics, etc. in a Phase 1 study.
Exam progress
The study initiated dosing in the first subject on March 22, 2026 (U.S. time).
Information on the U.S. Phase I clinical trial has been registered and made publicly available in the U.S. clinical trial database, ClinicalTrial.gov.